HCAT analyst estimates
Health Catalyst (HCAT) analyst ratings, the average price target and its range, and every firm's latest call.
- 6 firms rate HCAT: 0 buy, 6 hold, 0 sell.
- The average price target is $1.78 from None analysts, from $1.75 to $1.80.
HCAT analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Aug 20, 2026 | Canaccord Genuity | Canaccord downgrades Health Catalyst to Hold on transformation risk | $1.80 |
| Jul 21, 2026 | Canaccord Genuity | Health Catalyst price target raised to $3 from $2 at Canaccord | $3.00 |
| Jun 26, 2026 | Wells Fargo | Health Catalyst price target raised to $1.75 from $1 at Wells Fargo | $1.75 |
| May 12, 2026 | Stephens | Health Catalyst price target lowered to $1.75 from $2 at Stephens | $1.75 |
| Mar 13, 2026 | Canaccord Genuity | Health Catalyst Inc. (HCAT) PT Lowered to $2 at Canaccord | $2.00 |
| Mar 13, 2026 | Raymond James | Health Catalyst Inc. (HCAT) PT Lowered to $3 at Cantor Fitzgerald; No Turnaround Yet | $3.00 |
| Oct 8, 2025 | KeyBanc | Health Catalyst price target lowered to $4 from $5 at KeyBanc | $4.00 |
| Oct 8, 2025 | Evercore ISI | Health Catalyst price target lowered to $3 from $4 at Evercore ISI | $3.00 |
| Aug 29, 2025 | Summit Redstone Partners | Health Catalyst price target lowered to $5 from $9 at Canaccord | $5.00 |
| Aug 29, 2025 | Canaccord Genuity | Health Catalyst price target lowered to $5 from $9 at Canaccord | $5.00 |
| Apr 16, 2025 | KeyBanc | Health Catalyst price target lowered to $5 from $7 at KeyBanc | $5.00 |
| Mar 6, 2025 | Stephens | Health Catalyst price target lowered to $5 from $7 at Stephens | $5.00 |
| Jan 14, 2025 | RBC Capital | Health Catalyst price target lowered to $7 from $9 at RBC Capital | $7.00 |
| Sep 3, 2024 | Canaccord Genuity | Canaccord Genuity Reiterates Buy Rating on Health Catalyst Inc. (HCAT) | $11.00 |
| Aug 26, 2024 | Piper Sandler | Health Catalyst Inc. (HCAT) PT Lowered to $11 at Piper Sandler | $11.00 |